Effectiveness and Safety of Mirabek Sustained-release 50 mg Tablets in Korean Patients with Overactive Bladder: A Multicenter Observational Study at Tertiary General Hospitals

Background and objective: Mirabegron, a first-in-class β3-adrenergic agonist, is a key therapy for overactive bladder (OAB). This study aimed to evaluate the real-world effectiveness and safety of generic mirabegron (Mirabek) in Korean patients with OAB through a multicenter, prospective, noninterve...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jee Soo Park, Jongchan Kim, Moon-Hwa Park, Won Sik Jang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-12-01
coleção:	European Urology Open Science
Assuntos:	Beta-3 adrenergic receptor agonists Mirabegron Mirabek Overactive bladder Observational study
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2666168325014272
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!